Abstract
The clinical benefit of thrombolytic therapy for patients experiencing acute cerebral ischaemia has been demonstrated by both clinical trials and phase IV studies. However, such treatments must be initiated in a rapid manner, with treating physicians adhering to strict protocols designed to minimise delays and maximise safety. The efficacy of intravenous drug administration has been established with alteplase (recombinant tissue plasminogen activator; tPA) and ancrod, but only if these drugs can be administered within 3 hours of symptom onset. The use of alteplase beyond this timeframe, or outside of established protocols, may be hazardous. The use of alternative intravenous thrombolytic agents, such as streptokinase, also appears hazardous. Intra-arterial delivery of thrombolytic drugs such as pro-urokinase may extend clinical benefit to the 6-hour time frame.
Similar content being viewed by others
References
Fletcher AP, Alkjaersig N, Lewis M, et al. A pilot study of urokinase therapy in cerebral infarction. Stroke 1976; 7(2): 135–42
Wardlaw JM, Warlow CP. Thrombolysis in acute ischemic stroke: does it work? Stroke 1992; 23(12): 1826–39
Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory ischemia. Neurology 1992; 42(5): 976–82
Haley Jr EC, Brott TG, Sheppard GL, et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group. Stroke 1993; 24(7): 1000–4
del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992; 32(1): 78–86
Brott TG, Haley Jr EC, Levy DE, et al. Urgent therapy for stroke: part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23(5): 632–40
Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274(13): 1017–25
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995 Dec 14; 333(24): 1581–7
Hacke W, Bluhmki E, Steiner T, et al. Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS I. Stroke 1998; 29(10): 2073–5
Steiner T, Bluhmki E, Kaste M, et al. The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study. Cerebrovasc Dis 1998 Jul–Aug; 8(4): 198–203
Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283(9): 1145–50
Buchan AM, Barber PA, Newcommon N, et al. Effectiveness of t-PA in acute ischemic stroke: outcome relates to appropriateness. Neurology 2000; 54(3): 679–84
Chiu D, Krieger D, Villar-Cordova C, et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998; 29(1): 18–22
Grond M, Stenzel C, Schmulling S, et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998; 29(8): 1544–9
Wang DZ, Rose JA, Honings DS, et al. Treating acute stroke patients with intravenous tPA. The OSF Stroke Network experience. Stroke 2000; 31(1): 77–81
Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000; 283(9): 1151–8
Clark WM, Wissman S, Albers GW, et al. Recombinant tissuetype plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999 Dec 1; 282(21): 2019–26
Clark WM, Albers GW, Madden KP, et al. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thrombolytic therapy in acute ischemic stroke study investigators. Stroke 2000; 31(4): 811–6
Albers GW, Clark WM, Madden KP, et al. The ATLANTIS t-PA acute stroke trial: results forpatients treated within three hours of stroke onset. Stroke 2000; 33(2): 493–6
Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352(9136): 1245–51
Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicenter Acute Stroke Trial — Europe Study Group. N Engl J Med 1996 Jul 18; 335(3): 145–50
Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial — Italy (MAST-I) Group. Lancet 1995 Dec 9; 346(8989): 1509–14
Donnan GA, Davis SM, Chambers BR, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996; 276(12): 961–6
Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999 Dec 1; 282(21): 2003–11
Sherman DG, Atkinson RP, Chippendale T, et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA 2000 May 10; 283(18): 2395–403
Madden KP. Thrombolytic therapy for stroke. Marshfield Clin J 2001; 2: 39–52
Acknowledgements
No sources of funding were used in the preparation of this manuscript and the author has no financial relationships that are directly relevant to the contents of this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Madden, K. Optimal Timing of Thrombolytic Therapy in Acute Ischaemic Stroke. Mol Diag Ther 16, 213–218 (2002). https://doi.org/10.2165/00023210-200216040-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-200216040-00001